Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Convin SA ; 2023
    In:  Mediterranean Journal of Rheumatology Vol. 34, No. 2 ( 2023-06), p. 163-
    In: Mediterranean Journal of Rheumatology, Convin SA, Vol. 34, No. 2 ( 2023-06), p. 163-
    Type of Medium: Online Resource
    ISSN: 2529-198X
    Language: English
    Publisher: Convin SA
    Publication Date: 2023
    detail.hit.zdb_id: 3019943-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Rheumatology, Oxford University Press (OUP), Vol. 58, No. 5 ( 2019-05-01), p. 869-873
    Abstract: Despite the widespread clinical use of MTX in PsA, data from published randomized controlled studies suggest limited efficacy. The objective of the present study was to document the efficacy of MTX. Methods This was an open-label, prospective study of patients satisfying the ClASsification criteria for Psoriatic ARthritis study (CASPAR) criteria for PsA who received MTX in doses of ⩾15 mg/week throughout the follow-up period of 9 months. Disease activity was assessed across various domains by tender and swollen joint count, physician and patient global assessment, DAS-28 ESR, Clinical Disease Activity Index for PsA (cDAPSA), Leeds Dactylitis Instrument basic, Leeds Enthesitis Index (LEI), Psoriasis Area and Severity Index (PASI), Minimal Disease Activity and HAQ (CRD Pune version) at baseline and at 3, 6 and 9 months of follow-up. Response to therapy was assessed by EULAR DAS28 ESR, Disease Activity Index for PsA (cDAPSA) response, HAQ response and PASI75. MTX dose escalation and the use of combination DMARDS were dictated by disease activity. Results A total of 73 patients were included, with mean (s.d.) age 44 (9.7) years. The mean (s.d.) dose of MTX used was 17.5 (3.8) mg/week. Seven patients received additional DMARDS (LEF/SSZ). At the end of 9 months, significant improvement (P 〈 0.05) was noted in the tender joint count, swollen joint count, global activity, DAS-28ESR, cDAPSA, Leeds Dactylitis Index basic, LEI, PASI and HAQ. Major cDAPSA response was achieved in 58.9% of patients. EULAR DAS28 moderate and good response was achieved in 74% and 6.8% of patients, respectively. Minimal Disease Activity was achieved in 63% of patients. A PASI75 response and HAQ response was achieved in 67.9% and 65.8% of patients, respectively. Conclusion MTX initiated at ⩾15 mg/week with targeted escalation resulted in significant improvement in the skin, joint, dactylitis, enthesitis and functional domains of PsA.
    Type of Medium: Online Resource
    ISSN: 1462-0324 , 1462-0332
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 1474143-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    SAGE Publications ; 2021
    In:  Lupus Vol. 30, No. 11 ( 2021-10), p. 1725-1731
    In: Lupus, SAGE Publications, Vol. 30, No. 11 ( 2021-10), p. 1725-1731
    Abstract: Despite current advances in treatment, refractory lupus nephritis (RLN) continues to pose a challenge. The present paper studies the clinical profile and treatment outcomes in patients with RLN. Methods This observational, bidirectional study enrolled consecutive lupus nephritis (LN) patients from August 2018 to January 2019, who either failed to improve within three months, did not achieve partial renal response (PR) at six months, or did not achieve complete renal response (CR) after two years of treatment. Patients were followed every three months; treatment details and outcomes [CR, PR, no renal response (NR)], doubling serum creatinine, and death were recorded. Group comparisons were made using ANOVA and chi-square test. Factors affecting renal response were studied using linear regression. Results Forty-five of forty-eight enrolled patients completed at least nine months of follow-up and were included in outcome analysis. The median (IQR) SLE duration was three years (2-6 years). The majority of patients (n = 25) had proliferative LN (ISN/RPS class III/IV), with nine patients having pure membranous LN (class V). The mean activity and chronicity indices were 8 and 0. Over a median (IQR) follow-up period of 15 (12-27) months, 28 had CR, 9 had PR, and 8 showed no response to a switch in an immunosuppressive (IS) agent. Repeat renal biopsy (n = 8) with a mean (±SD) biopsy interval of 2 (±1) years showed histological class transformation in more than half of the patients. There was no significant difference in treatment outcome and time to attain response based on individual IS agent or sequence of IS agents used. None of the variables (duration of SLE or nephritis, baseline SLEDAI, leukopenia, hypertension, elevated anti-dsDNA, low complements, serum albumin, 24-hour urinary protein, biopsy class) predicted renal response on univariate analysis. No patient had a doubling of serum creatinine or progression to end-stage renal disease. There were three deaths, all related to infection. Conclusion A change in immunosuppression produces response in most RLN patients while a fifth of them showed no response to therapy. No predictor of renal response was identified. Histologic class switch was frequent. Renal function did not decline over a year of follow-up.
    Type of Medium: Online Resource
    ISSN: 0961-2033 , 1477-0962
    RVK:
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2021
    detail.hit.zdb_id: 2008035-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2023
    In:  Rheumatology Vol. 62, No. Supplement_2 ( 2023-04-24)
    In: Rheumatology, Oxford University Press (OUP), Vol. 62, No. Supplement_2 ( 2023-04-24)
    Abstract: IgG4-related sclerosing disease is a systemic disease characterized by extensive IgG4-positive plasma cells and T-lymphocyte infiltration of various organs and tumour-like involvement of one or more exocrine glands or other extranodal sites. The major involved organs are the salivary glands, lacrimal glands, pancreas and retroperitoneal space. Cardiac masses in IgG4 disease include hematoma, tumours, vegetations, calcific lesions and other rare conditions. Cardiac tumours are rare and have a variety of benign and malignant entities. We herein report the case of a patient with antiphospholipid antibody syndrome with a mass lesion in the right atrium, histologically proven as IgG4-related disease. Methods A 52-year-old female, a known case of primary antiphospholipid antibody syndrome for 14 years, with five first trimester abortions and positive lupus anticoagulant, on anticoagulation with vitamin K antagonist, presented with: shortness of breath, bilateral lower limb swelling and exertional dyspnoea- grade 3, since one week before admission, associated with orthopnoea, without any h/o decreased urine output or facial puffiness. On examination, she had hypertension with raised JVP and loud P2 possibilities of myocarditis, hypertensive heart failure, and severe PAH with CCF were considered. Investigations showed iron deficiency anaemia, normal complements, and negative anti-dsDNA antibodies. she was treated with diuretics, PDE inhibitors and antihypertensives, 2D echo showed haziness in the right atrium, possible thrombus (1.5 × 2.3 cm), CTPA - showed enhancing mass lesion in right atrium wall, neoplastic origin was considered. Results To further evaluate the mass in the right atrium, a PET scan was performed, which showed a metabolically active isolated mass lesion in the right atrium, Cardiac MRI showed an ill-defined lobulated T1 hypointense, T2/STIR isointense lesion involving the right atrial wall, possible lymphoma/sarcoma. Planned for excision/debulking via sternotomy approach, intraoperative trans oesophageal echo showed right atrial mass of 25 cms possibility of lymphoma/sarcoma, during surgery mass could not be excised but a biopsy was taken and sent for histopathological analysis. The report was suggestive of IgG4 disease, plasma cells stain positive for IgG4 with ratio of IgG4 to IgG of 0.4. IHC results showed no evidence of malignancy. Serum IgG4 levels was 145mg/dl ( & lt;135mg/dl). Diagnosis of IgG4 disease was made and the patient was started on steroids, repeat 2D echo after 6 months showed that the mass in the right atrium had resolved and the patient was asymptomatic. Conclusion In conclusion, this was a rare case of primary antiphospholipid antibody syndrome, presenting as a cardiac mass which was difficult to distinguish from malignant lymphoma by a pathological examination alone, hence a biopsy was done to analyze the clonality of the cardiac tumour and accurate diagnosis of IgG4-RD was made. Disclosure K. Yerram: None. P. Devarasetti: None. L. Rajasekhar: None.
    Type of Medium: Online Resource
    ISSN: 1462-0324 , 1462-0332
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2023
    detail.hit.zdb_id: 1474143-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2022
    In:  Rheumatology Vol. 61, No. Supplement_1 ( 2022-04-23)
    In: Rheumatology, Oxford University Press (OUP), Vol. 61, No. Supplement_1 ( 2022-04-23)
    Abstract: Short-term mortality in patients with SLE and high disease activity approaches 30% as reported by various studies. Raised serum interferon-alpha levels are observed in patients with active SLE. In mice studies interferon alpha(IFNα) delivered through adenovirus vector to lupus prone mice, caused rapid development of glomerulonephritis and death within 18 weeks. The aim was to study the value of interferon alpha in predicting short-term mortality in patients of SLE with high disease activity. Methods Serum samples of consecutive SLE patients with high disease activity (SLEDAI & gt;12) and age more than 18 years admitted in NIMS Rheumatology ward and acute medical care (AMC) were analyzed for interferon alpha levels with IFNα ELISA kit (ELAB science). Patients admitted for any other reason and having SLEDAI less than 12 were excluded. Demographic details and SLEDAI were recorded simultaneously. Patients who survived and discharged were considered as survivor group and those who succumbed during admission were considered as non-survivors. Between groups, difference in mean interferon alpha level was calculated using unpaired t test. Binomial logistic regression was applied to IFNα levels, dsDNA and SLEDAI as for predicting in-hospital mortality. Using ROC curve, area under curve was calculated for IFNα as a predictor of in-hospital mortality. Patients or legal guardian provided written informed consent for the study. Study was approved by the Institute ethics committee. Results Seventy patients with SLEDAI & gt;12 were admitted to ward (n = 62) or AMC (n = 18) from November 2020 to August 2021.Those excluded were age & lt;18 (n = 6), SLEDAI & lt;12 (n = 10), overlap syndromes (n = 8), patients with infection (n = 11). Mean age of the patients was 27.6±8.9 years. Mean duration of hospitalization was 8±4 days. 12 patients died in hospital and 58 survived. Mean days to death was 5±1 days. Mean SLEDAI (23.6±6.1, 18±5.6 p = 0.05), mean dsDNA (3.1±2.1, 1.7±1.8 p = 0.05) and mean serum IFNα levels in pg/ml (318.8±190.1, 39.9±74.7 p = & lt;0.001) was higher in non-survivors than survivors. On applying binomial logistic regression, serum interferon alpha predicted in-hospital mortality (p = & lt;0.001) while dsDNA(p = 0.4) and SLEDAI (p = 0.5) did not. Area under curve for predicting death was 0.9 for IFNα,0.74 for SLEDAI and 0.7 for dsDNA. A serum interferon alpha level of 140 pg/ml was the best predictor of in-hospital mortality with sensitivity of 84 %and specificity of 94%. Conclusion In-hospital mortality in patients with high disease activity is 17%. dsDNA, SLEDAI and serum interferon levels are predictors of in-hospital mortality. Among these serum IFNα is the best predictor of in-hospital mortality. Disclosure K. yerram: None. P. Devarasetti: None. L. Rajasekhar: None.
    Type of Medium: Online Resource
    ISSN: 1462-0324 , 1462-0332
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2022
    detail.hit.zdb_id: 1474143-X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Scientific Scholar ; 2021
    In:  Indian Journal of Cardiovascular Disease in Women Vol. 06 ( 2021-08-27), p. 100-105
    In: Indian Journal of Cardiovascular Disease in Women, Scientific Scholar, Vol. 06 ( 2021-08-27), p. 100-105
    Abstract: Systemic lupus erythematous–associated pulmonary arterial hypertension (SLE-PAH) is one of the important causes of mortality in lupus patients. Different autoantibodies are associated with SLE-PAH which can predict its future development. The objective of the study was to identify distinct autoantibody-based clusters in SLE-PAH patients and to compare demographic characters, clinical phenotypes, and therapeutic strategy across the clusters. Three distinct autoantibody clusters were identified using k-means cluster analysis in 71 SLE-PAH patients. Cluster1 had predominant Sm-RNP, Smith, SS-A association; cluster 2 had no definite autoantibody association; and cluster 3 was associated with nucleosome, histone, dsDNA, and ribosomal P protein. Patients in cluster 3 had a highly active disease while those in cluster 1 had significant cytopenia. Mean age and mean right ventricular systolic pressure (RVSP) were both high in cluster 2, indicating later-onset PAH in this group. This was the first autoantibody-based cluster analysis study in SLE-PAH patients in India which confirmed that autoantibodies did exist as clusters and the presence of definite autoantibodies can predict future development of pulmonary hypertension in these patients.
    Type of Medium: Online Resource
    ISSN: 2455-7854
    Language: English
    Publisher: Scientific Scholar
    Publication Date: 2021
    detail.hit.zdb_id: 2913570-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Indian Journal of Rheumatology, Medknow, Vol. 10, No. 3 ( 2015-09), p. 129-132
    Type of Medium: Online Resource
    ISSN: 0973-3698
    Language: English
    Publisher: Medknow
    Publication Date: 2015
    detail.hit.zdb_id: 2541837-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    Convin SA ; 2022
    In:  Mediterranean Journal of Rheumatology Vol. 33, No. 4 ( 2022-12), p. 449-
    In: Mediterranean Journal of Rheumatology, Convin SA, Vol. 33, No. 4 ( 2022-12), p. 449-
    Type of Medium: Online Resource
    ISSN: 2529-198X
    Language: English
    Publisher: Convin SA
    Publication Date: 2022
    detail.hit.zdb_id: 3019943-8
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Lupus, SAGE Publications, Vol. 30, No. 2 ( 2021-02), p. 336-341
    Abstract: Bronchiolitis obliterans organizing pneumonia (BOOP) is a clinico-patho-radiological diagnosis which rarely presents as a pulmonary manifestation of lupus. In this concise report, organizing pneumonia was found as the sole pulmonary manifestation of SLE in different age groups. Method All three patients diagnosed with SLE according to SLICC 2012 classification criteria, were admitted in rheumatology ward of NIMS hospital, Hyderabad, India from May to November, 2018. Their diagnosis of BOOP was either biopsy proven or imaging guided. Review of literature was done with MeSH terms (SLE, BOOP) in PubMed and approximately 10 articles were reviewed including latest of 2019 published in Scientific Reports. Result There were three patients – one juvenile lupus and two adults. Two patients were male and one female. All three patients had SLE with high disease activity. They all had organising pneumonia as pulmonary manifestation with other organ involvement. Juvenile patient had a fatal outcome while the others had a good recovery with steroid and immunosuppressive. Conclusion BOOP is a rare pulmonary manifestation in lupus. It can be diagnosed early with more precision using computerised tomography of lung without waiting for biopsy report. This will result in a better prognosis by rapid initiation of corticosteroid and immunosuppressive treatment.
    Type of Medium: Online Resource
    ISSN: 0961-2033 , 1477-0962
    RVK:
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2021
    detail.hit.zdb_id: 2008035-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2021
    In:  Immunologic Research Vol. 69, No. 1 ( 2021-02), p. 18-25
    In: Immunologic Research, Springer Science and Business Media LLC, Vol. 69, No. 1 ( 2021-02), p. 18-25
    Type of Medium: Online Resource
    ISSN: 0257-277X , 1559-0755
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2079303-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages